Literature DB >> 30739537

Novel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II-Induced Microvascular Dysfunction.

Elena Y Senchenkova1, Janice Russell1, Alper Yildirim1,2, D Neil Granger1, Felicity N E Gavins1.   

Abstract

Hypertension is an established risk factor for subsequent cardiovascular diseases, with Ang II (angiotensin II) playing a major role in mediating thrombotic and inflammatory abnormalities. Although T cells and IL-6 (interleukin-6) play an important role in adaptive immune responses, little is known about their role(s) in the thromboinflammatory responses associated with Ang II. Here we show using intravital microscopy coupled with the light/dye injury model that Rag-1 deficient (Rag-1-/-) and IL-6 deficient (IL-6-/-) mice are afforded protection against Ang II-induced thrombosis. Blocking IL-6 receptors (using CD126 and gp130 antibodies) significantly diminished Ang II-mediated thrombosis and inflammatory cell recruitment in mice. Furthermore, the adoptive transfer of IL-6-/--derived T cells into Rag-1-/- mice failed to accelerate Ang II-induced thrombosis compared with Rag-1-/- mice reconstituted with wild-type-derived T cells, suggesting T cell IL-6 mediates the thrombotic abnormalities associated Ang II hypertension. Interestingly, adoptive transfer of WT T cells into Rag-1-/-/Ang II mice resulted in increased numbers of immature platelets, which constitutes a more active platelet population, that is, prothrombotic and proinflammatory. To translate our in vivo findings, we used clinical samples to demonstrate that IL-6 also predisposes platelets to an interaction with collagen receptors, thereby increasing the propensity for platelets to aggregate and cause thrombosis. In summary, we provide compelling evidence for the involvement of IL-6, IL-6R, and T-cell-dependent IL-6 signaling in Ang II-induced thromboinflammation, which may provide new therapeutic possibilities for drug discovery programs for the management of hypertension.

Entities:  

Keywords:  angiotensin II; hypertension; inflammation; interleukin-6; thrombosis

Mesh:

Substances:

Year:  2019        PMID: 30739537      PMCID: PMC6422352          DOI: 10.1161/HYPERTENSIONAHA.118.12286

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  57 in total

1.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Role of T lymphocytes and interferon-gamma in ischemic stroke.

Authors:  Gokhan Yilmaz; Thiruma V Arumugam; Karen Y Stokes; D Neil Granger
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

3.  Protein kinase A determines platelet life span and survival by regulating apoptosis.

Authors:  Lili Zhao; Jun Liu; Chunyan He; Rong Yan; Kangxi Zhou; Qingya Cui; Xingjun Meng; Xiaodong Li; Yang Zhang; Yumei Nie; Yang Zhang; Renping Hu; Yancai Liu; Lian Zhao; Mengxing Chen; Weiling Xiao; Jingluan Tian; Yunxiao Zhao; Lijuan Cao; Ling Zhou; Anning Lin; Changgeng Ruan; Kesheng Dai
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

4.  Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension.

Authors:  Soni Savai Pullamsetti; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

Review 5.  Microvascular thrombosis models in venules and arterioles in vivo.

Authors:  Rolando E Rumbaut; Dick W Slaff; Alan R Burns
Journal:  Microcirculation       Date:  2005 Apr-May       Impact factor: 2.628

6.  Interleukin-6 is a potent thrombopoietic factor in vivo in mice.

Authors:  T Ishibashi; H Kimura; Y Shikama; T Uchida; S Kariyone; T Hirano; T Kishimoto; F Takatsuki; Y Akiyama
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

7.  Induction of in vitro human lymphocyte migration by interleukin 3, interleukin 4, and interleukin 6.

Authors:  K Bacon; A Gearing; R Camp
Journal:  Cytokine       Date:  1990-03       Impact factor: 3.861

Review 8.  The prothrombotic state in hypertension and the effects of antihypertensive treatment.

Authors:  Sunil Nadar; Gregory Y H Lip
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

Review 9.  IL-6 in inflammation, immunity, and disease.

Authors:  Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-04       Impact factor: 10.005

10.  Vascular inflammatory cells in hypertension.

Authors:  David G Harrison; Paul J Marvar; Jens M Titze
Journal:  Front Physiol       Date:  2012-05-07       Impact factor: 4.566

View more
  14 in total

1.  Targeting AnxA1/Formyl Peptide Receptor 2 Pathway Affords Protection against Pathological Thrombo-Inflammation.

Authors:  Shantel A Vital; Elena Y Senchenkova; Junaid Ansari; Felicity N E Gavins
Journal:  Cells       Date:  2020-11-13       Impact factor: 6.600

2.  Tocilizumab for treatment of mechanically ventilated patients with COVID-19.

Authors:  Emily C Somers; Gregory A Eschenauer; Jonathan P Troost; Jonathan L Golob; Tejal N Gandhi; Lu Wang; Nina Zhou; Lindsay A Petty; Ji Hoon Baang; Nicholas O Dillman; David Frame; Kevin S Gregg; Dan R Kaul; Jerod Nagel; Twisha S Patel; Shiwei Zhou; Adam S Lauring; David A Hanauer; Emily Martin; Pratima Sharma; Christopher M Fung; Jason M Pogue
Journal:  medRxiv       Date:  2020-06-03

Review 3.  Relationship Between ACE2 and Other Components of the Renin-Angiotensin System.

Authors:  Jordana B Cohen; Thomas C Hanff; Adam P Bress; Andrew M South
Journal:  Curr Hypertens Rep       Date:  2020-06-26       Impact factor: 5.369

Review 4.  Pathological Role of Angiotensin II in Severe COVID-19.

Authors:  Wolfgang Miesbach
Journal:  TH Open       Date:  2020-06-26

5.  A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis.

Authors:  Chang Fan; Fu Rong Wu; Jia Fu Zhang; Hui Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-12       Impact factor: 2.629

6.  Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.

Authors:  Morry Silberstein
Journal:  Int Immunopharmacol       Date:  2020-09-11       Impact factor: 4.932

7.  Maternal fecal microbiome predicts gestational age, birth weight and neonatal growth in rural Zimbabwe.

Authors:  Ethan K Gough; Thaddeus J Edens; Hyun Min Geum; Iman Baharmand; Sandeep K Gill; Ruairi C Robertson; Kuda Mutasa; Robert Ntozini; Laura E Smith; Bernard Chasekwa; Florence D Majo; Naume V Tavengwa; Batsirai Mutasa; Freddy Francis; Lynnea Carr; Joice Tome; Rebecca J Stoltzfus; Lawrence H Moulton; Andrew J Prendergast; Jean H Humphrey; Amee R Manges; Shine Trial Team
Journal:  EBioMedicine       Date:  2021-06-15       Impact factor: 8.143

Review 8.  Thromboinflammation in coronavirus disease 2019: The clot thickens.

Authors:  Raayma Iffah; Felicity N E Gavins
Journal:  Br J Pharmacol       Date:  2021-07-19       Impact factor: 9.473

9.  From ACE2 to COVID-19: A multiorgan endothelial disease.

Authors:  Richard A Stein; Lauren M Young
Journal:  Int J Infect Dis       Date:  2020-09-05       Impact factor: 3.623

10.  The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series.

Authors:  C M Magro; J J Mulvey; J Laurence; S Sanders; A N Crowson; M Grossman; J Harp; G Nuovo
Journal:  Br J Dermatol       Date:  2020-09-15       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.